AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 252 min read$GMAB

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study o

Genmab (GMAB) reported updated Phase 2 trial data for petosemtamab, showing 75% and 67% objective response rates in 1L and 2L mCRC patients, respectively. The study, presented at ESMO 2026, supports ongoing Phase 3 trials. Petosemtamab, targeting EGFR and LGR5, is being evaluated in multiple solid tumors. Genmab will host an investor update on October 28.

Original reporting
gurufocus.com
Published Oct 25, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 12:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$GMABBullishMed
01

Why it matters

The updated efficacy numbers provide a concrete catalyst for short‑term price movement and set expectations for the Phase 3 read‑outs.

02

Market read

Positive Phase 2 data may lift Genmab and related biotech stocks ahead of upcoming Phase 3 trials.

03

What to watch

Upcoming Phase 3 trial design and competitive landscape in colorectal cancer could affect long‑term upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Genmab is a Copenhagen‑based biotech with several approved antibodies; petosemtamab is in Phase 2 and moving toward four Phase 3 LiGeR trials.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab released updated Phase 2 follow‑up data showing 75% ORR in 1L and 67% in 2L metastatic colorectal cancer patients.

Expected impact

likely upward pressure as investors price in improved efficacy and upcoming Phase 3 trials.

Evidence & confidence

High response rates and durable disease control are material clinical milestones that typically lift biotech valuations.

Market effects

Sector

strengthens the EGFR/LGR5 bispecific antibody space and may boost peer biotech valuations.

Regional

European biotech markets could see modest gains on the data.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Skeptics may argue the data set is small and safety signals (IRRs) could temper enthusiasm.

Key entities

  • company
    Genmab A/S

    International biotech developing petosemtamab.

  • drug
    Petosemtamab (GEN1158)

    Bispecific antibody targeting EGFR and LGR5.

Read at source← All news

StoryGenmab reports 75% and 67% objective response rates in Phase 2 colorectal cancer trial

Also covered by

2 outlets

Related articles

OCT 25
$GMABHighAI 9/10

Genmab A/S: Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Genmab (GMAB) reported updated Phase 2 trial results for petosemtamab in metastatic colorectal cancer, showing 75% and 67% objective response rates in first- and second-line settings, respectively. The data supports ongoing Phase 3 trials and was presented at ESMO Congress 2026. Petosemtamab is an investigational bispecific antibody targeting EGFR and LGR5.

finanznachrichten.de3 min
OCT 25
$GMABMedAI 8/10

Genmab reports phase 2 trial data for colorectal cancer drug

Genmab (NASDAQ:GMAB) reported Phase 2 trial data for petosemtamab in metastatic colorectal cancer, showing 75% and 67% response rates in first- and second-line patients, respectively. The trial involved 79 patients and was presented at the European Society for Medical Oncology Congress 2026. Genmab is conducting four Phase 3 trials and will host an investor update.

investing.com2 min
OCT 25
$GMABMedAI 8/10

Genmab A/S (GMAB) Reports 75%/67% ORR in Phase 2 mCRC

Genmab reported updated Phase 2 data for petosemtamab plus chemo in metastatic colorectal cancer, showing 75% ORR in 1L and 67% in 2L, with 81% in 1L left-sided tumors. Median follow-up was 5.9 and 7.1 months. Most responses were confirmed. This update supports Genmab’s shift into late-stage GI oncology.

tradingview.com2 min
OCT 24
$GMABMed

Genmab and Incyte agree to colorectal cancer trial

Genmab and Incyte will collaborate on a Phase 1/2 trial combining Genmab's petosemtamab with Incyte's INCB161734 and chemotherapy for first-line colorectal cancer with KRAS G12D mutation. Genmab will lead the study, with Incyte co-funding and supplying its drug. Both companies' shares closed at $43.79 and $115.71 respectively before the announcement.

mugglehead.com2 min